Physician profile

Chadd Dee Nelson

Internal Medicine · Randolph Air Force Base, TX

NPI 1619904679

$1,210.48

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $156.09 2019-2020
Amgen INC. $123.59 2019
Astrazeneca Pharmaceuticals LP $117.96 2019
Glaxosmithkline, LLC. $105.44 2019-2020
Pfizer INC. $95.33 2019-2020
Sanofi-Aventis U.S. LLC $86.02 2019-2020
Novo Nordisk INC $85.61 2019-2020
Janssen Pharmaceuticals, INC $59.59 2019-2020
E.R. Squibb & Sons, L.L.C. $59.36 2019-2020
Astellas Pharma US INC $56.32 2019-2020
Lilly USA, LLC $49.94 2019-2020
Novartis Pharmaceuticals Corporation $38.74 2019
Strongbridge US INC. $33.72 2019
Shire North American Group INC $31.48 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $26.28 2019
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Insulet Corporation $18.61 2019
Supernus Pharmaceuticals, INC. $16.87 2019
Dynavax Technologies Corporation $15.04 2019
Merck Sharp & Dohme LLC $11.73 2019
Abbott Laboratories $11.65 2021
Genentech USA, INC. $11.11 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Chadd Dee Nelson

$1,210.48

in general payments reported 2019-2025

Years
2019-2021
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/1007172/chadd-dee-nelson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.